Q2-osavuosiraportti
Vain PDF
77 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
2 805
Myynti
Määrä
5 629
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 2 167 | - | - | ||
| 108 | - | - | ||
| 2 | - | - | ||
| 3 | - | - |
Ylin
7,075VWAP
Alin
6,865VaihtoMäärä
2,2 315 040
VWAP
Ylin
7,075Alin
6,865VaihtoMäärä
2,2 315 040
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten1 päivä sittenAnd here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.
·5 t sittenThanks for a very good answer again. You are damn sharp 💪. Personally, as I have written before, biotech is gold or bust, but I have always believed since 2017 that this will become something. But I've been through ups and downs. And I will probably chip in a bit more if there is an emission down at the 5-range. But in total of what I have, my investment is at 4% or something around there of total. So for me, I'm in for the long haul. But it's a shame how one reads on Discord where there is almost a deification of everything that happens in the company. Many go in believing that it's impossible to lose here. But yes, as you say, it really is possible 👍🏻 By the way, what happened to that super promoter donjasmino 😂😂·3 min sittenHaha just have to laugh a little now. To put it this way, I'm not a person who whines and complains that much. But I had a fantastic experience on Discord for Cereno today, I was blocked because I wrote against someone who thought it was Rea(rabatt) now on kurs-snack. I'll probably hold my shares, but like you GM99 quite the realist. So yes, there are many pumpers. Better to listen to the thread here 👌
·2 päivää sittenPhase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·2 päivää sittenPoistettu·2 päivää sitten10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…- ·2 päivää sitten4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?2 päivää sitten2 päivää sittenA CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·2 päivää sittenThanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.
·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
77 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenAnd here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.·5 t sittenThanks for a very good answer again. You are damn sharp 💪. Personally, as I have written before, biotech is gold or bust, but I have always believed since 2017 that this will become something. But I've been through ups and downs. And I will probably chip in a bit more if there is an emission down at the 5-range. But in total of what I have, my investment is at 4% or something around there of total. So for me, I'm in for the long haul. But it's a shame how one reads on Discord where there is almost a deification of everything that happens in the company. Many go in believing that it's impossible to lose here. But yes, as you say, it really is possible 👍🏻 By the way, what happened to that super promoter donjasmino 😂😂·3 min sittenHaha just have to laugh a little now. To put it this way, I'm not a person who whines and complains that much. But I had a fantastic experience on Discord for Cereno today, I was blocked because I wrote against someone who thought it was Rea(rabatt) now on kurs-snack. I'll probably hold my shares, but like you GM99 quite the realist. So yes, there are many pumpers. Better to listen to the thread here 👌
- ·2 päivää sittenPhase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·2 päivää sittenPoistettu·2 päivää sitten10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…
- ·2 päivää sitten4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?2 päivää sitten2 päivää sittenA CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·2 päivää sittenThanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
- ·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
2 805
Myynti
Määrä
5 629
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 2 167 | - | - | ||
| 108 | - | - | ||
| 2 | - | - | ||
| 3 | - | - |
Ylin
7,075VWAP
Alin
6,865VaihtoMäärä
2,2 315 040
VWAP
Ylin
7,075Alin
6,865VaihtoMäärä
2,2 315 040
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
77 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenAnd here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.·5 t sittenThanks for a very good answer again. You are damn sharp 💪. Personally, as I have written before, biotech is gold or bust, but I have always believed since 2017 that this will become something. But I've been through ups and downs. And I will probably chip in a bit more if there is an emission down at the 5-range. But in total of what I have, my investment is at 4% or something around there of total. So for me, I'm in for the long haul. But it's a shame how one reads on Discord where there is almost a deification of everything that happens in the company. Many go in believing that it's impossible to lose here. But yes, as you say, it really is possible 👍🏻 By the way, what happened to that super promoter donjasmino 😂😂·3 min sittenHaha just have to laugh a little now. To put it this way, I'm not a person who whines and complains that much. But I had a fantastic experience on Discord for Cereno today, I was blocked because I wrote against someone who thought it was Rea(rabatt) now on kurs-snack. I'll probably hold my shares, but like you GM99 quite the realist. So yes, there are many pumpers. Better to listen to the thread here 👌
- ·2 päivää sittenPhase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·2 päivää sittenPoistettu·2 päivää sitten10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…
- ·2 päivää sitten4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?2 päivää sitten2 päivää sittenA CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·2 päivää sittenThanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
- ·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
2 805
Myynti
Määrä
5 629
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 2 167 | - | - | ||
| 108 | - | - | ||
| 2 | - | - | ||
| 3 | - | - |
Ylin
7,075VWAP
Alin
6,865VaihtoMäärä
2,2 315 040
VWAP
Ylin
7,075Alin
6,865VaihtoMäärä
2,2 315 040
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 315 040 | 315 040 | 0 | 0 |